Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.10 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | a small-molecule pocket | 0.60 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 6 Parkinson's papers of 2,450 | 0.74 |
| pathways Reactome | 8 pathways; mostly dopamine synapse | 1.00 |
No case: the score is under the bar. Receipt 2763
Sealed predictions
- LMNA in dopamine neurons, braak-0.58 (p 0.102) → -0.25 (p 0.508)receipt 2771
Swarm cases
receipt 2771: LMNA in dopamine neurons, braak
- power
- full sample -0.44 (p 0.067, n 18), 95% CI -0.75 to +0.03. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.48 (p 0.043, n 18). holds up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.66 (p 0.0030, n 18). not the mix.
- skeptic
- leave-one-out range -0.54 to -0.36, sign flips 0; without severely affected donors -0.44 (p 0.067, n 18). robust.
- cell type
- strongest in oligodendrocytes: -0.63 (p 0.0051, n 18) vs -0.44 in dopamine neurons. proposing oligodendrocytes.
- axis
- no measure beats "tracks Braak Lewy-body stage" for LMNA in dopamine neurons.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up LMNA · oligodendrocytes · braak: substantia nigra, an independent cohort (Parkinson's or LBD vs controls) -0.10 p 0.722 (needs p < 6.6e-4)
Receipts
loading the receipts